For children with AML in CR1, the major consolidation therapies are BMT, ABMT and intensive chemotherapy. The relative effectiveness of these strategies is still debated. We conducted a systematic review and meta-analysis of trials to determine the effectiveness of BMT and ABMT in CR1 in paediatric AML. Eligible studies enrolled patients Ͻ21 years from 1985 to 2000 with AML in CR1. Two groups of studies were identified: (1) Those comparing the outcome of patients with and without a histocompatible family donor; and (2) Randomised controlled trials (RCT) comparing ABMT with non-myeloablative chemotherapy. The relative risk statistic was calculated for outcomes of interest in each trial. If there was no excessive heterogeneity between trials the results were pooled, and an overall relative risk and risk difference for treatment effect across trials were calculated. Results of the analysis showed that allocation to BMT reduced risk of relapse and improved disease-free and overall survival. For ABMT, heterogeneity of effect between RCTs prevented pooling of results. In conclusion, BMT from a histocompatible family donor improves patient outcome. Data are insufficient to determine whether this is true for all subgroups of AML, and whether ABMT is superior to non-myeloablative chemotherapy. An individual patient data meta-analysis is required to further evaluate the available data. Bone Marrow Transplantation (2002) 29, 843-852. DOI: 10.1038/sj/bmt/1703528 Keywords: ABMT; AML; pediatric; systematic review; meta-analysis The prognosis of paediatric AML has improved over the last four decades. Currently more than 80% of children diagnosed with AML achieve remission. In half of these patients remission is sustained and long-term cure achieved.
The prognosis of paediatric AML has improved over the last four decades. Currently more than 80% of children diagnosed with AML achieve remission. In half of these patients remission is sustained and long-term cure achieved. 1 For patients achieving remission, BMT has been considered the treatment of choice if a matched sibling donor (MSD) is available. 2 The advantages of BMT in maintaining remission are balanced by mortality, related mainly to the complications of infection and GVHD, and the long-term toxicity of treatment. The overall survival advantage for BMT is not clear, particularly as chemotherapy becomes more intensive. It is unclear if all subgroups of AML benefit equally from BMT. BMT in CR1 may not be the best therapy for a good prognosis AML patient with a reduced risk of relapse and an improved salvage rate following relapse.
There have been no randomised clinical trials (RCTs) comparing BMT with other forms of post-remission therapy in children or adults. BMT is widely believed to be the most effective anti-leukaemic therapy available in AML. Consequently RCTs have not been believed to be ethical. 'Mendelian' or 'biologic' randomisation has been used to compare BMT with other therapies. The outcome of all patients with a matched sibling donor (MSD) is compared to those without, in trials where BMT is recommended for all patients with a MSD. Such Mendelian randomisation in a 'donor vs no donor' study is regarded as an unbiased method of comparing intervention effects in the absence of true RCTs. 3, 4 The major treatment options for AML patients with no MSD, are ABMT, further intensive post-remission nonmyeloablative chemotherapy or no further therapy.
1,2,5-8 A number of studies have randomised children to receive ABMT or chemotherapy, [9] [10] [11] [12] and others have compared ABMT with no further therapy. [13] [14] [15] AML is a heterogenous disease with a number of morphologic and cytogenetic subtypes. These have been associated with better or worse prognosis within AML. In the United Kingdom Medical Research Council's 10th AML trial (MRC AML 10), patients classified into good, standard and poor risk subgroups (by cytogenetics and responsiveness to initial chemotherapy) had a risk of relapse of 33%, 51% and 78%. 16 The Berlin-Frankfurt-Munster (BFM) group have used morphological group and day 15 marrow to determine a standard risk and high risk group, with an event-free survival (EFS) of 68% for the standard risk patients and 33% for high risk patients in BFM 87. 17, 18 Stratification of patients into such risk groups and evaluation of response to different treatments (eg BMT vs ABMT vs chemotherapy) within these risk groups would assist in identifying the appropriate treatment strategy for an individual patient.
In this systematic review, the effect of BMT and ABMT on relapse and survival in paediatric AML patients in CR1 is described. The first aim of this review was to determine the effectiveness of BMT and ABMT in preventing relapse and improving survival beyond 3 years after first remission in paediatric AML. Secondly, we wished to determine the effectiveness of BMT and ABMT in preventing relapse and improving survival beyond 3 years after first remission in good risk groups, standard and poor risk groups of AML in children.
Patients and methods

Eligible studies
Two types of studies were eligible: prospective cohort studies on paediatric AML comparing the outcome of patients with and without a histocompatible family donor, and RCTs on paediatric AML comparing ABMT with other treatments (non-myeloablative consolidation chemotherapy or no further therapy). The prospective cohort studies included were those which (1) Had an explicit policy of tissue typing family members of patients and recommending BMT to all patients in CR1 who had a histocompatible family donor (HLA 5 or 6/6 match). For convenience, we refer to such donors as 'matched sibling donors' (MSD); (2) Allocated patients to BMT or comparative therapy groups exclusively on the basis of donor availability; and (3) Compared the outcome of patients in the donor/BMT group with patients in the no donor/comparative therapy group using intention to treat analysis.
For both types of study, only trials enrolling patients from 1985 to 2000 were included, since BMT was not widely recommended for all patients with a MSD prior to 1985 and transplantation supportive care after 1985 would be sufficiently comparable to current practice. Eligible studies were paediatric trials reporting AML patients less than 21 years old, who achieved CR1 and were treated within a paediatric oncology unit and/or on a treatment protocol of a collaborative paediatric oncology group. Studies that treated children on adult protocols within adult units were not eligible.
Outcome measures
Outcomes of interest were relapse after remission, survival and disease-free survival (DFS) with a follow-up time of 3 or more years and treatment-related mortality (TRM, defined as all deaths in remission in all studies). As all participants in the donor vs no donor comparisons had survived induction and achieved remission, DFS and EFS are equivalent outcome measures.
Search strategies
Relevant studies were identified by electronic searching of the Cochrane Controlled Trials Register, Medline, Embase, CancerLit and registers of current cancer trials (CancerNet and the UKCCCR Register of Cancer Trials), by handsearching of 17 specialist journals and conference proceedings from three societies. Citations from identified trials and relevant reviews were also followed. Researchers participating in comparative trials in paediatric AML were contacted to identify unpublished studies.
Data extraction
Studies identified from the above sources were screened independently by three reviewers for the eligibility criteria specified above. If this could not be done satisfactorily from the title and abstract, a full text version of the published study was obtained for assessment. Two reviewers using a data extraction pro forma independently performed data extraction. Methodological quality of eligible trials was independently assessed unblinded by two reviewers using the full-text article and a simple quality assessment system. Kappa scores for agreement between investigators on three study quality assessment criteria were determined. If incomplete information was provided in the published report, we sought additional data from the authors.
Statistical analysis
All analyses were performed according to original treatment allocation (intention-to-treat analysis). Relative risk (RR) and absolute risk difference were calculated for each outcome measure in each trial. Quantitative (MantelHaenszel heterogeneity test statistic 19 ) and qualitative heterogeneity between trials was evaluated. If there was no evidence of excessive qualitative or quantitative heterogeneity between trials, the results were pooled and an overall RR and absolute risk reduction for treatment effect across all trials were calculated, using DerSimonian and Laird random effects model. 20 Analyses were conducted with the latest version of the Cochrane statistical package, Revman 4.1. For analysis of time-to-event data, the hazard ratio was estimated using information reported in the included studies (the logrank P value, the number of patients allocated to each treatment group and number of events in each allocated treatment group). The log rank expected number of events and variance were used to calculate the log hazard ratio (HR) for individual trials. In the absence of excessive heterogeneity, the log HR for individual trials were then combined to give an overall log HR, calculated using methods described by Parmer et al 21 (method 4.3 formula 13, 11 and 4 with an overall log hazard ratio calculated as a weighted average of the individual log hazard ratios according to formulas 1 and 2). To investigate treatment effect within risk groups, data were extracted on outcomes of patients stratified by prognostic risk as defined in the MRC AML 10 trial. 16 
Results
Description of studies
Six prospective cohort studies comparing the outcome of paediatric AML patients with and without an MSD fulfilled the inclusion criteria.
9,11-13,22, 23 The characteristics of these six studies are shown in Table 1 . The proportion of patients with an MSD who received an MSD BMT ranged from 72 to 100% and was greater than 90% in four of the six studies.
Four RCTs comparing ABMT with other treatment were identified. [9] [10] [11] [12] [13] [14] In three RCTs patients were randomized between ABMT and further chemotherapy, [9] [10] [11] [12] while one RCT compared ABMT with no further therapy.
13, 14 The characteristics of these four RCTs are shown in Table 2 . All of these randomised comparisons were conducted within prospective multicentre trials involving inception cohorts of paediatric AML patients. Patients were eligible for randomisation if they achieved CR and did not have an MSD. Between 50% and 73% of eligible patients were random- Table 1 Characteristics of included studies in systematic review of BMT for paediatric AML in first remission Complete remission after 1-vs chemotherapy 2 courses of induction chemotherapy Excluded DS, sAML, MDS, M0, biphenotypic leukemia DS ϭ Downs syndrome; sAML ϭ secondary AML; MDS ϭ myelodysplastic syndrome; GS ϭ granulocytic sarcoma.
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ised and between 54% and 100% of randomised patients received their allocated treatment.
Fourteen studies were excluded from the systematic review of BMT for the following reasons: no intention to treat analysis, 10, [25] [26] [27] [28] [29] [30] insufficient data to determine quality of study, [31] [32] [33] no published or unavailable unpublished data (CCG 2961, unpublished; POG 9421 unpublished), BMT for high risk AML only 18 and outcome not from time of remission. 34 All reported randomised controlled trials of ABMT were included in the meta-analysis of ABMT.
Outcomes: donor vs no donor studies of BMT
Relapse: The proportion of patients suffering relapse was significantly lower in the donor than in the no donor group in the pooled result from five studies 9, [11] [12] [13] 23, 24 in which proportion of relapse was reported (RR 0.59, 95% CI 0.48-0.72) (Figure 1 ). This corresponded to a reduced risk of relapse of 18% (Table 3 ). The crude mean risk of relapse in the no MSD group across trials was 44.2%, whilst the relapse rate amongst those with donors was 23.9%. There Table 2 Characteristics of included randomised controlled trials in systematic review of ABMT for paediatric AML in first remission The HR, estimated from the log-rank statistic, was only available for the CCG 2891 11, 12 and LAME 89/91 24 trial. The pooled HR was 0.53 (95% CI 0.39-0.70), indicating patients in the MSD group had a reduced hazard of relapse compared to the no donor group.
Disease-free survival:
The proportion of patients who relapsed or died following treatment was significantly lower in the MSD group than in the no donor group in the pooled result from all six included studies (RR 0.71 95% CI 0.58-0.86) (Figure 1 ). There was no significant heterogeneity between trials in risk difference, however quantitative heterogeneity in relative risk was found ( 2 ϭ 9.66, 5 df, P ϭ 0.085). The pooled HR calculated for the three trials 11, 12, 22, 24 for which time-to-event data was available was 0.67 (95% CI 0.58-0.81) with patients with an available donor having a reduced hazard of relapse or death.
Overall survival: In each of the four trials 11, 12, 13, 22, 23 in which overall survival (OS) was reported, the RR of death was reduced in the MSD group, but this effect was only statistically significant in one of the trials. 11, 12 In the individual trials the risk of death for patients with MSDs was reduced by 6% to 25%. Whilst the studies showed the same direction of effect, there was heterogeneity in the magnitude of effect for RR ( 2 ϭ 9.51, 3 df, P ϭ 0.023) and risk difference ( 2 ϭ 7.58, 3 df, P ϭ 0.056). A pooled result for the overall risk of death was determined as the direction of effect was consistent across studies. The pooled RR of death was 0.68 (95% CI 0.48-0.95) (Figure 1 ) with an absolute difference risk difference of death of 15% (95% CI 0.05-0.25) ( Table 3 ). The pooled HR calculated for the three trials [11] [12] [13] 22 for which time-to-event data were available were 0.69 (95% CI 0.58-0.83), with the MSD group having a reduced hazard of death.
Treatment-related mortality:
The absolute number of deaths was small in each individual study. There was gross heterogeneity in direction of effect in TRM. In the MRC AML10 trial 13 TRM was higher in the donor group. In contrast, three of the other trials 9,11,12,24 reported a higher TRM amongst patients lacking an MSD who underwent alternative post-remission therapy (Figure 1) . The apparent effect, however, was not statistically significant in any of the four trials.
Randomised controlled trials of ABMT
The results are summarised in Figure 2 and Table 4 . For each outcome of interest there was qualitative heterogeneity, with or without statistically significant quantitative heterogeneity. For this reason it was inappropriate to present a pooled estimate of effect for RR or HR statistics.
Relapse: Only the POG 8821 trial 10 showed that the ABMT group had a significantly lower risk of relapse than the control group (RR 0.70, 95% CI 0.53-0.93). The risk of relapse in the ABMT and chemotherapy group was 41% and 58%, respectively, with a risk difference of 17% (95% CI 4-30%). Total (95% CI) Figure 2 ABMT for paediatric AML in CR1 outcome of randomised controlled trials.
Disease-free survival:
The MRC AML10 study 13, 14 was the only trial that found an improved DFS in the ABMT group. Unlike the other three studies, it compared ABMT with no further therapy and showed a significantly reduced risk of relapse or death in the ABMT group (RR 0.59, 95% CI 0.37-0.96 and HR 0.49, 95% CI 0.27-0.89).
Overall survival: In the CCG 2891 trial, 11, 12 the OS was significantly lower in the patients randomised to ABMT (RR 1.34, 95% CI 1.06-1.70 and HR 1.43, 95% CI 1.04-1.97). The risk difference was 0.14 (95% CI 0.03-0.25). There was no significant difference in the risk of death between ABMT and control groups in the POG8821 study 10 and the UK MRC 10 trial. 13, 14 Treatment-related mortality: TRM was low (less than 6%) in the AEIOP LAM 87 9 and MRC AML 10 13,14 studies 849  Table 4 Outcome of randomised controlled trials of ABMT vs chemotherapy and ABMT vs no further therapy for paediatric acute myeloid leukemia in first remission: relative risk and risk difference for individual trials Relative risk indicates risk of adverse event in donor group relative to the no donor group. Absolute risk difference indicates the percentage reduction in absolute risk of adverse outcome in the donor group compared to the no donor group b Risk reductions are presented only for trials in which there was a significantly reduced relative risk of the adverse event in one of the treatment groups and did not differ significantly between ABMT and control groups. However in the POG8821 study 10 where marrow was purged for autograft, TRM was significantly higher (10%) in the ABMT group compared to the chemotherapy controls (RR 3.73, 95% CI 1.07-13.03). TRM was not reported in CCG 2891.
11,12
Treatment effect in different risk groups
None of the six cohort studies or four RCTs presented stratified treatment outcomes according to morphological or cytogenetic risk groups of paediatric AML. The MRC AML 10 trial 13, 14 reported the outcome of paediatric patients in good, standard and poor risk cytogenetic-morphological risk groups, but this was not presented according to intervention groups. Although this analysis included data on 2200 children with AML achieving complete remission in 10 clinical trials, treatment effect in different risk groups could not be evaluated based on published data.
Discussion
This review has summarised the best available evidence on the effect of BMT and ABMT in paediatric AML. Ten trials of BMT or ABMT of adequate methodological quality were identified, representing over 2200 children with AML in CR. 9, [11] [12] [13] [22] [23] [24] Amongst these studies, patients allocated to BMT on the basis of having an MSD available were found to have a reduced risk of relapse and an improved DFS and OS, compared to patients without donors. The risk of relapse in remission, if there is an MSD available for consolidation therapy with BMT, is reduced by 18% whilst the risk of death is reduced by around 15%. A reduced risk of relapse with BMT was shown in all trials and was statistically significant for the larger studies. The risk of death was also consistently reduced amongst patients allocated to BMT, although the magnitude of the effect varied between studies.
Four RCTs of ABMT vs other post-remission treatment strategies in paediatric AML were identified.
9-14 The sum-
Bone Marrow Transplantation
marised results represent the best available evidence on the effect of ABMT for consolidation therapy in paediatric AML in CR1 amongst patients lacking an MSD. Substantial heterogeneity existed between the included RCTs in the outcomes of relapse, DFS, OS and TRM. It was therefore not appropriate to present summary scores for outcome effects. Therefore, there was insufficient evidence to determine the effect of ABMT compared to chemotherapy, or no further therapy, in preventing relapse or death in paediatric AML in CR1. It was not possible to comment on the value of BMT or ABMT for subgroups of AML with different risks of relapse. Our conclusions are only valid if our results are accurate. This assumes that: (1) donor vs no donor studies are a valid method of quasi-randomisation; (2) pooling of data from studies with different follow-up periods is appropriate; (3) the interventions used in the included studies were qualitatively similar; and (4) a high proportion of patients received the allocated treatment.
It is generally accepted that donor vs no donor studies are a valid method of quasi-randomisation. Such studies have no deliberate treatment allocation for an individual. The observed outcome is, therefore, less likely to be caused by baseline differences between patient groups and potential confounding factors are more likely to be distributed evenly between groups. Furthermore, these studies avoid the survivor bias present in studies that simply compare the outcome of patients receiving BMT with other management strategies. The studies selected for inclusion in the systematic review all fulfilled the quality criteria of allocation to treatment group solely on the basis of MSD availability and implementation of intention-to-treat analysis. Although it is difficult to establish intention to transplant, we specifically required that the trials stated a requirement for patients in CR1 to be tissue typed and the outcome analysed on this basis. In five 9, 11, 12, [22] [23] [24] of the six trials, investigators reported that donor and no donor patient groups were comparable on the basis of known prognostic variables at baseline. In three 9, 22, 24 of the six studies, data were available demonstrating these similarities. One can therefore be confident that the observed improved patient outcome in the donor group reflects a true intervention effect. Our strict entry criteria resulted in the exclusion of several other studies in the analysis.
One clear limitation of this systematic review and metaanalysis is the pooling of data from studies with different follow-up times (28 months to 7 years). This would also be addressed by updating individual patient data from the included studies and using a standard follow-up time across the pooled studies. Pooling of studies with different followup times is not ideal but, as most events occur before 3 years, combining data with follow-up times of 3 or more years was therefore considered reasonable. [9] [10] [11] [12] [13] [14] [22] [23] [24] There are potentially important differences between the studies included in the interventions that were compared. Heterogeneity in outcome between the ABMT trials may relate to differences between the trials in the details of ABMT or control intervention. Such differences included comparison of ABMT vs no further therapy, 13, 14 rather than comparison with further non-myeloablative chemotherapy; [9] [10] [11] [12] comparison with chemotherapy control intervention with [10] [11] [12] or without 9,13,14 the use of high-dose cytarabine; and the use of purging and different conditioning regimens (TBI vs chemotherapy) in the ABMT group. There were not sufficient numbers of studies to perform meaningful subgroup analysis.
In the included studies there was some variability in the proportion of patients who actually received the treatment to which they were allocated. Incomplete compliance with the intended post-remission therapy means that the difference in intervention effect is likely to be underestimated. The proportion of patients with donors who actually received BMT, ranged from 72% to 100%. This is an acceptable proportion of patients overall, comparing favourably with compliance with allocated interventions in many RCTs. If more patients with donors had received BMT, the intervention effect may have been even more apparent. The patients randomised to ABMT or control formed only a small proportion of the total patient numbers in the trials (50-73%). Compliance with allocation to chemotherapy or ABMT was poor in some trials (54-100%). In many cases the results in individual trials found no significant difference between ABMT and control groups, which may partially reflect the fact that many patients did not receive the intended intervention.
There is no doubt that a substantial proportion of children with AML can be cured by chemotherapy. There is also no doubt that BMT from an MSD still offers the best chance of DFS and OS overall. There is, however, an urgent need to identify which patients will benefit most, or least, from more intensive therapy and BMT. This systematic review was able to determine the average effect of BMT on relapse and survival for paediatric patients with AML. AML is a heterogeneous group of disorders and individual patients have quite different baseline risks of relapse and death following remission. In MRC AML 10, patients classified into good, standard and poor risk subgroups had a baseline risk of relapse after remission of around 33%, 51% and 78% respectively. 16 It is unlikely that the intervention effect of BMT is of the same magnitude within each risk group. Although it is hypothesised that BMT will be of greatest advantage within the poor or standard risk groups, it may also offer benefit to those in the good risk group. None of the reports included here allowed evaluation of this hypothesis.
Prospective RCTs remain the gold standard for evaluation of treatment effect in populations and subgroups. However, if the newly formed Children's Oncology Group initiates a frontline protocol for AML in 2001/2002, the result of this study will not be known for around 10 years. It is therefore vital that the best use be made of the available data. Meta-analysis of the published data does not allow treatment effect within risk groups to be determined. Our conclusions are that these data should be re-analysed using individual patient data (IPD). IPD meta-analysis is a form of meta-analysis recognised as a gold standard, particularly in the context of clinical trials using time to event outcome data. [35] [36] [37] [38] IPD meta-analysis is based on individual patient data, in which the separate trial results used in the metaanalysis come from the central analysis of the raw data from each trial. Updated information on each patient entered into each study is collected centrally. The data for each trial are then analysed separately to obtain summary statistics. Patients are therefore compared directly only with other patients in the same trial. For the purposes of therapy for paediatric AML, the main benefit of IPD meta-analysis is the ability to undertake subgroup analyses for important hypotheses about difference in effect. This would allow us to determine if the morphological and cytogenetic risk groups identified from MRC AML 10 and BFM are generally applicable. An additional potential benefit of an IPD analysis is the possibility of including data from the many excluded studies and re-evaluating them using intentional to treat analysis. Individual patient meta-analyses are particularly well suited to summarising and synthesising the data from cancer trials, as has already been done for AML for induction therapy, 39 as well as for other diagnoses. 35, 40, 41 Allocation of patients to MSD BMT reduced the risk of relapse significantly and improved DFS and OS. The average effect of MSD BMT is to reduce risk of relapse by 18% and improve survival by 15%. From a clinician's perspective, this means that in order to prevent one death amongst children with AML in first remission one needs to perform seven MSD BMTs. The survival advantage provided by BMT needs to be considered in the context of the risks of the procedure. These include short-and long-term morbidity, quality of life and financial costs. These were not addressed in the included studies.
In the absence of conclusive evidence, both ABMT and non-myeloablative chemotherapy appear to be reasonable treatment options for paediatric AML patients lacking an MSD. As the relapse rate tended to be lower amongst patients randomised to ABMT in both the POG 8821 and MRC AML 10 trial, it could be argued that ABMT would be the preferred current treatment option. However, given the marginal benefit and the reduced rate of attainment of second remission for patients who relapse after ABMT, a better strategy may be to continue intensive chemotherapy for those patients without an MSD and look for an alternative allogeneic donor in the event of poor response or relapse with chemotherapy alone.
